New York, NY – In a sponsored podcast interview with peer-reviewed Natural Medicine Journal, University of Utah Brain Institute researcher Deborah Yurgelun-Todd, Ph.D., discusses the cognitive health benefits of Cognizin® Citicoline, as well as describes her most recent research, including new data presented at the New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting, organized by the American Society of Clinical Psychopharmacology and the National Institutes of Health.
In research presented at the NCDEU Annual Meeting, University of Utah Brain Institute researchers found that individuals receiving either a low (250 mg) or high (500 mg) dose of citicoline produced fewer errors during performance testing compared to the placebo group. Findings suggest that citicoline supplementation at 250 mg provided improved attention when required, due to the inhibition of incorrect responses.?
Dr. Yurgelun-Todd also highlights results of a unique six-week neuroimaging study conducted at Harvard Medical School's McLean Hospital. Participants were administered both the Stroop task, which is designed to measure attention and reaction time, and the Morris Water Maze task, which examines spatial memory, while simultaneously undergoing functional Magnetic Resonance Imaging (fMRI). Subjects were then given a daily oral dose of either 500 or 2000 mg of Cognizin for six weeks before a second imaging protocol was conducted.
After taking Cognizin, participants showed improved accuracy in generating correct responses, better spatial memory retrieval and increased brain metabolism. Results were nearly identical for individuals receiving 500 mg and 2000 mg of Cognizin, confirming that statistically significant improvements in attention, focus, memory and recall can be achieved at dosing levels of 500 mg.
In addition to discussing Cognizin's role in improving various facets of brain function including attention, memory and recall, Dr. Yurgelun-Todd also highlights Cognizin's role in mitigating mental health issues such as depression and addiction, its mechanism of action in the body, as well as safety and tolerability findings.
The approximately 25-minute podcast is available until July 31. It can be found here:
Cognizin is a branded form of Citicoline, a natural substance found in every cell of the body and especially vital to brain health.* Citicoline is broken down during intestinal absorption and, after passing through the blood/brain barrier, is reconstituted in the brain as citicoline.* Citicoline is a water-soluble compound that supplies precursors for the synthesis of phospholipids, including phosphatidyl- choline, a major constituent of brain tissue*; helps maintain normal levels of acetylcholine, a chemical that regulates memory and cognitive function*; enhances communication between neurons*; supports visual function*; protects neural structures from free radical damage*; enhances metabolism and healthy brain activity*; and helps sustain healthy cellular mitochondria for sustained energy*. Cognizin is also highly stable, GRAS, ultra-pure and allergen-free. For more information on Cognizin, visit www.cognizin.com. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Kyowa Hakko is an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. Kyowa is the maker of branded ingredients including Cognizin(R) Citicoline, Hydrafend™ Hyaluronic Acid, Lumistor® L-Hydroxyproline, Setria® Glutathione, Kyowa CoQ10™ as well as Sustamine™ L-Alanyl-L-Glutamine.
# # #
Courtney Jacobs Morton
Integrated Marketing Group
P: 801-538-0777 x102